• Explore /
  • Poster
  • / KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

Abstract Poster

Authors

null

Brian M. Slomovitz

Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, FL

Brian M. Slomovitz , David Cibula , Tayup Simsek , Mansoor Raza Mirza , Beata Maćkowiak-Matejczk , Emma Hudson , Ignacio Romero , Nicoletta Colombo , Jacob Korach , Rutie Yin , Lucy Gilbert , Kosei Hasegawa , Alexandra Tyulyandina , Sally E. Baron-Hay , Lyndsay Willmott , Floor Jenniskens Backes , Robert J. Orlowski , Xuan Zhou , Vivek Khemka , Sandro Pignata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT05173987

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5623)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5623

Abstract #

TPS5623

Poster Bd #

488a

Abstract Disclosures

Similar Posters

First Author: Christian Marth

First Author: Thomas Powles

First Author: Toshihiko Doi

First Author: Mario Javier Pineda